GenrAb

About GenrAb

GenrAb is dedicated to developing neuroprotective therapies for neurological diseases by harnessing the power of human immunity. Their mission is to fill a crucial gap in neurological care, prevent disease progression, and transform patient care through innovative treatments using their proprietary Antibody Gene Signature (AGS) technology.

Products & Services

Neuroprotective Agents:Therapies aimed at protecting and treating patients with neurological diseases, focusing on retarding disease progression.

TGM-010 (Lead Antibody):A lead monoclonal antibody targeting a conserved neurodegenerative pathway, showing promise in treating multiple neurologic disorders with proven preclinical efficacy in reducing disability.

Antibody Gene Signature (AGS) Technology:Proprietary technology that has identified over 400 potentially therapeutic fully-human monoclonal antibodies for neurological disorders.

Specialties

Neuroprotective Therapies Monoclonal Antibodies (mAbs) Neurological Disorders Treatment Immune-Centric Drug Discovery Antibody Gene Signature (AGS) Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 5600000 MR: - FA: 5.6 million FAN: 5600000	D: 2025-04-22 FD: 2025-04-22	5 investors

Seed Latest

2025-04-22

$5.6M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Larry Tiffany

CEO

B

Benjamin Greenberg

CMO

M

Martin Devenport

COO

R

Rich Vincent

CFO

N

Nancy Monson

CSO

N

Neil Warma

Board Director

View 5 more team members with Pro

Unlock Full Team Directory

Recent News

GenrAb Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised